SEELOS THERAPEUTICS INC - SEEL STOCK NEWS

Seelos Therapeutics, Inc. (Nasdaq: SEEL) will present at the 4th Annual ALS ONE Research Symposium on November 30, 2021. Raj Mehra, Ph.D., the CEO, will share insights on SLS-005, a trehalose injection intended for treating amyotrophic lateral sclerosis (ALS). This treatment is part of the HEALEY ALS Platform Trial, which aims to expedite the evaluation of multiple ALS therapies simultaneously. Trehalose is the fifth regimen in this groundbreaking trial, which collaborates with prominent institutions like the Northeast ALS Consortium.

Seelos Therapeutics, Inc. (Nasdaq: SEEL) announced that the FDA accepted its IND application for SLS-005 (trehalose injection) aimed at treating spinocerebellar ataxia (SCA). This treatment has received Fast Track designation and Orphan Drug status for SCA3 from both the FDA and European Medicines Agency. Previous studies showed stable SARA scores in patients, indicating potential efficacy. Seelos plans to initiate a global Phase IIb/III clinical study in early 2022, with funding secured from recent capital raises.

Seelos Therapeutics, Inc. (Nasdaq: SEEL), a biopharmaceutical company focused on central nervous system disorders, is set to participate in two upcoming investor conferences. The Guggenheim Healthcare Talks will occur on November 15-16, featuring 1x1 meetings hosted by CEO Raj Mehra and a fireside chat on November 16 at 2:20 PM ET. Additionally, Seelos will participate in The Benchmark Company 10th Annual Discovery on December 2, where Dr. Mehra will host virtual meetings. These events aim to enhance engagement with investors and provide insights into their advancing clinical pipeline.

Seelos Therapeutics (Nasdaq: SEEL) presented findings from the open-label study of SLS-002 (Intranasal Racemic Ketamine) at the IASR/AFSP International Summit on Suicide Research. The study indicated rapid and sustained reductions in depression and suicidality among 17 hospitalized subjects with Major Depressive Disorder at imminent risk of suicide. Notably, the mean scores on the Montgomery-Åsberg Depression Rating Scale showed remission by Day 6 post-treatment. SLS-002 aims to address a critical need for effective treatment options in this high-risk population.

Seelos Therapeutics (Nasdaq: SEEL) announced its selection to present at the IASR/AFSP International Summit on Suicide Research, taking place from October 24-27, 2021. On October 25, Tim Whitaker, M.D., will present a poster detailing a Phase 2 study on SLS-002 (Intranasal Racemic Ketamine) aimed at treating adults with Major Depressive Disorder at imminent risk of suicide. This research highlights the urgent need for effective treatments amid rising suicide rates in the U.S., with SLS-002 targeting an unmet medical need.

Seelos Therapeutics (Nasdaq: SEEL) announced its participation in two upcoming investor conferences: the M-Vest Advances in Mental Health Virtual Conference on September 22, 2021, and the Cantor Virtual Global Healthcare Conference from September 27 to 30, 2021. CEO Raj Mehra will discuss topics including depression treatment during the M-Vest panel and will take part in a fireside chat at the Cantor conference. These events highlight Seelos's commitment to advancing therapies for central nervous system disorders and rare diseases.

Seelos Therapeutics, Inc. (Nasdaq: SEEL) has appointed Dr. Margaret Dalesandro to its Board of Directors. Dr. Dalesandro brings over 30 years of biopharmaceutical experience, including senior roles at ImClone Systems, where she contributed to the $6.5 billion sale to Eli Lilly. Known for her expertise in drug development and commercialization, she is expected to enhance Seelos' late-stage clinical asset development. Dr. Dalesandro holds a Ph.D. in Biochemistry and leads Brecon Pharma Consulting LLC, emphasizing her significant industry impact.

Seelos Therapeutics (Nasdaq: SEEL) announced the promotions of Michael Golembiewski to Chief Financial Officer and Anthony Marciano to Chief Communications Officer, effective September 1, 2021. Golembiewski, with a strong financial background in biotechnology, joined Seelos in 2019 after roles at Agile Therapeutics and Pernix Therapeutics. Marciano has been with Seelos since 2017 and has extensive experience in investor relations. Additionally, several employees, including senior management, purchased shares in the open market last month, indicating confidence in the company's future.

Seelos Therapeutics (Nasdaq: SEEL) provided a mid-year business and clinical update, highlighting significant advancements in its clinical-stage drug programs. The SLS-002 study showing rapid antidepressant effects has progressed to a placebo-controlled Phase 2. The SLS-005 program for ALS is set to start patient dosing soon, supported by recent patent approvals. As of Q2 2021, Seelos reported $87.2 million in cash with no debt, enhancing its financial stability. The company was also added to multiple stock indices, signaling growing investor interest.